Downregulation of c-Myc determines sensitivity to 2-methoxyestradiol-induced apoptosis in human acute myeloid leukemia

Experimental Hematology

Volumn 36, Issue 2, 2008, Pages 140-148

  Chow, Jyh Ming ^a   Liu, Chien Ru ^b   Lin, Che Pin ^b   Lee, Chun Nin ^a   Cheng, Yun Chih ^a   Lin, Shufan ^a   Liu, H Eugene ^a,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; CASPASE 3; CASPASE 7; CELL PROTEIN; CYCLOHEXIMIDE; GENOMIC DNA; MESSENGER RNA; MYC PROTEIN; REACTIVE OXYGEN METABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL STRAIN HL 60; CELL STRAIN U937; CONTROLLED STUDY; DOWN REGULATION; ENZYME ASSAY; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LEUKEMIA CELL; MITOCHONDRION; ONCOGENE C MYC; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIA; NF-KAPPA B P50 SUBUNIT; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; REACTIVE OXYGEN SPECIES; TRANSCRIPTION FACTOR RELA; TUBULIN MODULATORS; U937 CELLS;

EID: 38149042802     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.10.004     Document Type: Article

References (38)

1. Cleveland J.L., and Kastan M.B. Cancer. A radical approach to treatment. Nature 407 (2000) 309-311
2. Kizaki M., Sakashita A., Karmakar A., Lin C.W., and Koeffler H.P. Regulation of manganese superoxide dismutase and other antioxidant genes in normal and leukemic hematopoietic cells and their relationship to cytotoxicity by tumor necrosis factor. Blood 82 (1993) 1142-1150
3. Huang P., Feng L., Oldham E.A., Keating M.J., and Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407 (2000) 390-395
4. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., and Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94 (1999) 2102-2111
5. Lee C., Lin Y., Huang M., et al. Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promyelocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo. Leuk Lymphoma 47 (2006) 521-529
6. Mooberry S.L. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 6 (2003) 355-361
7. Gao N., Rahmani M., Shi X., Dent P., and Grant S. Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress. Blood 107 (2006) 241-249
8. Zhou Y., Hileman E.O., Plunkett W., Keating M.J., and Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 101 (2003) 4098-4104
9. Gao N., Rahmani M., Dent P., and Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process. Oncogene 24 (2005) 3797-3809
10. Dang C.V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19 (1999) 1-11
11. Huang M.J., Cheng Y.C., Liu C.R., Lin S., and Liu H.E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 34 (2006) 1480-1489
12. Lin H.L., Liu T.Y., Wu C.W., and Chi C.W. 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 92 (2001) 500-509
13. Carothers A.M., Hughes S.A., Ortega D., and Bertagnolli M.M. 2-Methoxyestradiol induces p53-associated apoptosis of colorectal cancer cells. Cancer Lett 187 (2002) 77-86
14. Shimada K., Nakamura M., Ishida E., Kishi M., and Konishi N. Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 24 (2003) 1067-1075
15. Biroccio A., Benassi B., Filomeni G., et al. Glutathione influences c-Myc-induced apoptosis in M14 human melanoma cells. J Biol Chem 277 (2002) 43763-43770
16. Maehara K., Hasegawa T., and Isobe K.I. A NF-kappaB p65 subunit is indispensable for activating manganese superoxide: dismutase gene transcription mediated by tumor necrosis factor. J Cell Biochem 77 (2000) 474-486
17. Kumar A.P., Garcia G.E., Orsborn J., Levin V.A., and Slaga T.J. 2-Methoxyestradiol interferes with NF-kappaB transcriptional activity in primitive neuroectodermal brain tumors: implications for management. Carcinogenesis 24 (2003) 209-216
18. Li Y., and Sarkar F.H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated by Akt signaling pathway. Clin Cancer Res 8 (2002)
19. Brown K., Park S., Kanno T., Franzoso G., and Siebenlist U. Mutual regulation of the transcriptional activator NF-kappaB and its inhibitor, IkappaB-alpha. Proc Natl Scad Sci U S A 90 (1993) 2532-2536
20. Davison K., Cote S., Mader S., and Miller Jr. W.H. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 17 (2003) 931-940
21. Dai J., Weinberg R.S., Waxman S., and Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93 (1999) 268-277
22. Sordet O., Rebe C., Leroy I., et al. Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis. Blood 97 (2001) 3931-3940
23. Li Y.M., and Broome J.D. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 59 (1999) 776-780
24. Ling Y.H., Jiang J.D., Holland J.F., and Perez-Soler R. Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines. Mol Pharmacol 62 (2002) 529-538
25. Huang M.J., Hsieh R.K., Lin C.P., Chang I.Y., and Liu H.J. The cytotoxicity of arsenic trioxide to normal hematopoietic progenitors and leukemic cells is dependent on their cell-cycle status. Leuk Lymphoma 43 (2002) 2191-2199
26. Doza Y.N., Hall-Jackson C.A., and Cohen P. Arsenite blocks growth factor induced activation of the MAP kinase cascade, upstream of Ras and downstream of Grb2-Sos. Oncogene 17 (1998) 19-24
27. Ludwig S., Hoffmeyer A., Goebeler M., et al. The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6/p38-dependent pathway. J Biol Chem 273 (1998) 1917-1922
28. Shimada K., Nakamura M., Ishida E., Kishi M., Matsuyoshi S., and Konishi N. The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells. Mol Carcinog 39 (2004) 1-9
29. Chou W.C., Chen H.Y., Yu S.L., Cheng L., Yang P.C., and Dang C.V. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 106 (2005) 304-310
30. Hoffman B., Amanullah A., Shafarenko M., and Liebermann D.A. The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21 (2002) 3414-3421
31. Luo H., Li Q., O'Neal J., Kreisel F., Le Beau M.M., and Tomasson M.H. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated anti-apoptotic mutations. Blood 106 (2005) 2452-2461
32. Tong X., Yin L., Washington R., Rosenberg D.W., and Giardina C. The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. Mol Cell Biochem 265 (2004) 171-183
33. Mathas S., Lietz A., Janz M., et al. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 102 (2003) 1028-1034
34. Sharma S.V., Gajowniczek P., Way I.P., et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10 (2006) 425-435
35. Felsher D.W., and Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 4 (1999) 199-207
36. James J., Murry D.J., Treston A.M., et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 25 (2007) 41-48
37. Dahut W., Lakhani N., Gulley J., et al. Phase I clinical trial of oral 2-methoxyestradiol, an oral antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5 (2006) 22-27
38. Han G.Z., Liu Z.J., Shimoi K., and Zhu B.T. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res 65 (2005) 387-393